# Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation

> **NCT04492514** · PHASE2 · COMPLETED · sponsor: **Kristin Hudock** · enrollment: 1 (actual)

## Conditions studied

- COVID 19
- SARS-CoV 2
- Pneumonia

## Interventions

- **DRUG:** Mavrilimumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04492514
- **Lead sponsor:** Kristin Hudock
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-05-20
- **Primary completion:** 2020-11-16
- **Final completion:** 2020-11-16
- **Target enrollment:** 1 (ACTUAL)
- **Last updated:** 2024-12-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04492514

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04492514, "Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT04492514. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*